Takeda Pharma Buys into US

Marino, Jonathan
June 2009
Mergers & Acquisitions Report;6/29/2009, Vol. 22 Issue 26, p1
This article reveals the plan of Japanese drugmaker Takeda Pharmaceutical Co. to acquire Irvine, California-based IDM Pharma. The acquisition deal is valued at 75 million U.S. dollars. IDM shares surged by more than 50% on June 22, 2009 as a result of the all-cash offer. The primary drug of IDM that assists chemotherapy patients, MEPACT, will be operated under the Millennium oncology division of Takeda.


Related Articles

  • Struggling Bone Cancer Drug Maker Being Bought for $67M. Reed, Vita // Orange County Business Journal;5/25/2009, Vol. 32 Issue 21, p5 

    The article reports on the acquisition of IDM Pharma Inc. by Takeda Pharmaceutical Co. Ltd. for $67 million in Irvine, California. It is noted that the amount that IDM has been purchased is 55% more than its stock was trading at on May 15, 2009. It reveals that the move is part of the strategy...

  • Bone Cancer Drug Lures Takeda: $66.7M for IDM.  // Bioworld Week;5/25/2009, Vol. 17 Issue 21, p3 

    The article reports on the plan of Osaka, Japan-based Takeda Pharmaceutical Co. Ltd. to takeover the IDM Pharma Inc. that is based in Irvine, California. Takeda is to pay $66.7M for the acquisition and will purchase the drug Mepact which is indicated to treat non-metastatic osteosarcoma after...

  • Takeda Pharma Buys into US. Marino, Jonathan // Mergers & Acquisitions Report;5/25/2009, Vol. 22 Issue 21, p1 

    The article reports on the acquisition of IDM Pharma by Takeda Pharmaceutical Co., the largest drugmaker in Japan. It states that the offer has already been approved by the board of IDM Pharma. According to the article, the offer has sent the shares of IDM by over 50 percent. As part of the...

  • HEALTHCARE.  // Orange County Business Journal;5/25/2009, Vol. 32 Issue 21, p11 

    The article offers news briefs related to healthcare industry in California. Takeda Pharmaceutical Co. Ltd. has purchased IDM Pharma Inc. for $67 million. Beckman Coulter Inc. will sell its shares and debt to investors in order to increase its shares up to $750 million. Meanwhile, Clarient Inc....

  • 12 TAKEDA PHARMACEUTICAL CO.  // Contract Pharma;Jul/Aug2011, Vol. 13 Issue 6, p92 

    The article reports on the performance and plan of Osaka, Japan-based Takeda Pharmaceutical Co. Ltd. The company's pharma sales decline by four percent as it loses the patent protection for Prevacid. Its acquisition Nycomed is expected to add around 4.0 billion dollars to its revenues. It plans...

  • Takeda to Buy Nycomed.  // Chain Drug Review;6/6/2011, Vol. 33 Issue 10, p39 

    The article reports that Nycomed AS will be acquired by Japan-based Takeda Pharmaceuticals Co.

  • FDA-Stalled Bone Cancer Drug Lures Takeda: $66.7M for IDM. Osborne, Randy // BioWorld Today;5/19/2009, Vol. 20 Issue 95, p1 

    The article reports on the plan of Japan's Takeda Pharmaceutical Co. Ltd. to buy out U.S.-based IDM Pharma. The proposed buyout deal, valued at $66.7 million, reportedly took the U.S. firm from a threatened Nasdaq delisting to a price increase that nearly matched the premium Takeda will pay....

  • Takeda Completes Nycomed Acquisition.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p9 

    The article reports the acquisition of Takeda Pharmaceutical Co. Ltd., to the Switzerland's Nycomed amounting to 9.6 billion euros on a cash basis and it is in favor on the part of Takeda on their sustainable growth strategy.

  • Today's Transactions: Takeda Spends $800M on URL Pharma. NOTO, ANTHONY // Mergers & Acquisitions Report;4/16/2012, Vol. 25 Issue 16, p13 

    The article reports on the acquisition of URL Pharma Inc., a privately-held pharmaceutical research firm headquartered in Philadelphia, Pennsylvania, by Tokyo, Japan-based Takeda Pharmaceutical Co. for 800 million U.S. dollars.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics